JW (Cayman) Therapeutics Co. Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Viva Biotech Holdings

Frontage Holdings Corp.

JOINN Laboratories (China) Co., Ltd.

Kintor Pharmaceutical Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

Sirnaomics Ltd.

Sinomab Bioscience Ltd.

CanSino Biologics, Inc.

Beijing Lüzhu Biotechnology Co., Ltd.

JW (Cayman) Therapeutics Co. Ltd.

Ascletis Pharma, Inc.

Why is JW (Cayman) Therapeutics Co. Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Poor long term growth as Operating profit has grown by an annual rate 7.73% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -227.87

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -54.22%, its profits have risen by 56.5%

Below par performance in long term as well as near term

Along with generating -54.22% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is JW (Cayman) Therapeutics Co. Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

JW (Cayman) Therapeutics Co. Ltd.

-54.22%

-0.35

78.93%

Hang Seng Hong Kong

0.26%

0.01

20.12%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

214.84%

EBIT Growth (5y)

7.73%

EBIT to Interest (avg)

-167.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.31

Sales to Capital Employed (avg)

0.11

Tax Ratio

0.56%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.12

EV to EBIT

-1.51

EV to EBITDA

-2.15

EV to Capital Employed

1.23

EV to Sales

1.32

PEG Ratio

Dividend Yield

ROCE (Latest)

-81.25%

ROE (Latest)

-34.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

OPERATING CASH FLOW(Y)

Highest at HKD -467.94 MM

RAW MATERIAL COST(Y)

Fallen by -1,000.92% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -43.24 %

DEBTORS TURNOVER RATIO(HY)

Highest at 47.9 times

NET SALES(Q)

Highest at HKD 194.11 MM

OPERATING PROFIT MARGIN(Q)

Highest at -55.49 %

PRE-TAX PROFIT(Q)

Highest at HKD -89.77 MM

NET PROFIT(Q)

Highest at HKD -93.13 MM

-5What is not working for the Company

ROCE(HY)

Lowest at -64.64%

CASH AND EQV(HY)

Lowest at HKD 560.32 MM

Here's what is working for JW (Cayman) Therapeutics Co. Ltd.

Net Sales

At HKD 194.11 MM has Grown at 150.6%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (HKD MM)

Operating Cash Flow

Highest at HKD -467.94 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Net Sales

Highest at HKD 194.11 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Operating Profit Margin

Highest at -55.49 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at HKD -89.77 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Pre-Tax Profit

At HKD -89.77 MM has Grown at 62.06%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

Highest at HKD -93.13 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

Net Profit

At HKD -93.13 MM has Grown at 60.64%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

Debt-Equity Ratio

Lowest at -43.24 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 47.9 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -1,000.92% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for JW (Cayman) Therapeutics Co. Ltd.

Cash and Eqv

Lowest at HKD 560.32 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents